Capacity of Human Intravenous Immunoglobulin (IGIV3I) Production Process to Eliminate an Experimental TSE-Model Agent

2007 ◽  
Vol 119 (1) ◽  
pp. S263 ◽  
Author(s):  
J.M. Diez ◽  
H. Biescas ◽  
S. Caballero ◽  
R. Gajardo ◽  
J.I. Jorquera
Keyword(s):  
Production Process ◽  
Intravenous Immunoglobulin ◽  
Human Intravenous Immunoglobulin

Treatment of Severe Adverse Cutaneous Drug Reactions With Human Intravenous Immunoglobulin in Two Dogs

2006 ◽  
Vol 42 (4) ◽  
pp. 312-320 ◽  
Author(s):  
Tara K. Trotman ◽  
Heidi Phillips ◽  
Hilary Fordyce ◽  
Lesley G. King ◽  
Daniel O. Morris ◽  
...  
Keyword(s):  
Supportive Care ◽  
Intravenous Immunoglobulin ◽  
Poor Response ◽  
Skin Lesions ◽  
Wound Management ◽  
High Morbidity ◽  
Drug Reactions ◽  
Injectable Drugs ◽  
Cutaneous Drug Reactions ◽  
Human Intravenous Immunoglobulin

Severe adverse cutaneous reactions were documented in two dogs with acute skin lesions and systemic signs after exposure to several oral and injectable drugs. Because of the high morbidity and mortality rates of many severe cutaneous drug reactions and a poor response to supportive care, wound management, and conventional immunosuppressive therapy, human intravenous immunoglobulin (IVIG) was infused on 2 consecutive days (1 g/kg per day) after informed consent was received. Human IVIG, with supportive care, resulted in rapid resolution of dermatological and systemic signs in both dogs; this treatment may be considered in other cases of severe cutaneous drug reactions.

scholarly journals Subcutaneous Human Intravenous Immunoglobulin (IVIG) in the Treatment of Antibody Deficiency. ♦ 60

1997 ◽  
Vol 41 ◽  
pp. 12-12
Author(s):  
E Richard Stiehm ◽  
Adrian M. Casillas ◽  
Jerry Z. Finklestein ◽  
Kerry T. Gallagher ◽  
Paula K. Groncy ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Antibody Deficiency ◽  
Human Intravenous Immunoglobulin
Sign in / Sign up

Export Citation Format

Share Document